Colorectal Cancer Trial, Recruiting (NCT06327568)

Colorectal Cancer Trial, Recruiting NCT06327568 Sponsor: European Institute of Oncology Condition: Colorectal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06327568 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Colorectal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed through a tissue sample with high-grade abnormal cells in the anal area (AIN2+) or invasive anal cancer
People who have been diagnosed through a tissue sample with low-grade abnormal cells in the anal area (AIN1)
People considered at higher risk for anal cancer, including those with a weakened immune system (such as people living with HIV, those taking medications that suppress the immune system, or people who have had an organ transplant)
Men who have sex with men
Women aged 40 or older who have a history of high-grade abnormal cells or cancer of the cervix (CIN2+) and/or vulvar cancer
People with Crohn's disease affecting the anal or surrounding area
People currently taking part in colorectal cancer screening
People who have signed a written consent form agreeing to take part

Who may not be able to join:

People who decline to sign the written consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +390294372716

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06327568

Sponsor: European Institute of Oncology

Phase: Not Applicable

Status: Recruiting

Condition: Colorectal Cancer

Trial contact: +390294372716

More information: https://clinicaltrials.gov/study/NCT06327568

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed through a tissue sample with high-grade abnormal cells in the anal area (AIN2+) or invasive anal cancer
People who have been diagnosed through a tissue sample with low-grade abnormal cells in the anal area (AIN1)
People considered at higher risk for anal cancer, including those with a weakened immune system (such as people living with HIV, those taking medications that suppress the immune system, or people who have had an organ transplant)
Men who have sex with men
Women aged 40 or older who have a history of high-grade abnormal cells or cancer of the cervix (CIN2+) and/or vulvar cancer
People with Crohn's disease affecting the anal or surrounding area
People currently taking part in colorectal cancer screening
People who have signed a written consent form agreeing to take part

Who may not be able to join:

People who decline to sign the written consent form

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

European Institute of Oncology

Registry

ClinicalTrials.gov

Start date

17 June 2022

Est. completion

17 June 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov